Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Recently revised consensus targets for glycaemic management in patients with type 2 diabetes are challenging and require optimisation of dosing strategies for oral antidiabetic therapies. The demonstration of significant cardiovascular outcome benefits in metformin-treated type 2 diabetic patients enrolled in the United Kingdom Prospective Diabetes Study has established this agent as the first line oral therapy after diet failure in newly presenting overweight people with type 2 diabetes mellitus. The antihyperglycaemic efficacy of metformin increases with increasing daily doses between 500 mg and the upper limits of the recommended daily dosage ( ≥ 2000 mg/day). Although metformin is associated with gastrointestinal side-effects in up to 20% of patients, this is not generally dose related. Transient dose reduction, slower titration and taking the dose with meals may ameliorate the problem. Risk of lactic acidosis due to metformin is negligible when this agent is prescribed correctly, and is unrelated to the plasma metformin concentration. Intensification of metformin therapy within the dose range represents a rational and practical therapeutic strategy for optimising glycaemic control in patients who are suitable for, and tolerant of, metformin treatment. The recently introduced 1000 mg metformin tablet should facilitate the use of higher doses and may help treatment compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Cited by
Metformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658
“The increase in plasma lactate concentration with therapeutic doses of metformin is small, usually <2 mmol/L [3,14,15,98,99], although higher levelsmay occur [100].”
BackgroundMetformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Self-citationRepurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Golay, A. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803695 · Cited by 205
Metadata
- Authors
- Scarpello, J. H.
- Venue
- The British Journal of Diabetes & Vascular Disease
- Publisher
- SAGE Publications
- Published
- 2001-08
- Volume
- 1
- Issue
- 1
- Pages
- 28-36
- ISSN
- 1474-6514 (ISSN-L)
- 1753-4305
- OpenAlex
- W2111269218
- Cited by
- 44
- References
- 3
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. https://app.cochat.ai/papers/10.1177/14746514010010010501
- The paper
- Scarpello, J. H. (2001). Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. The British Journal of Diabetes & Vascular Disease. https://doi.org/10.1177/14746514010010010501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.